About: 1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment
Creator	Wolpe, P
source	Elsevier; PMC
abstract	The use of drugs to treat human disease is a pursuit that extends back into our evolutionary ancestors. Drugs are powerful substances with a great capacity to cause harm if misused or overused. Even when used correctly, pharmaceuticals can elicit disputes about their relative harms and benefits in specific situations. The establishment of modern intermediaries – physicians or pharmacists – in the allocation of the most powerful drugs increases the potential for conflict between those who control the resource and those who desire access to it. The size and influence of the pharmaceutical–industrial complex places disproportionate power in those whose interests lie in promoting and expanding pharmaceutical use in society. The expense of certain drugs complicates equitable allocation, and the concentration of pharmaceutical power in Western, industrialized countries promotes research and drug discovery disproportionately for diseases that are prevalent in the wealthier nations. The increasing sophistication of drug action challenges the traditional model of using drugs as a means to treat pathological conditions and processes, and raises the specter of lifestyle and enhancement uses of pharmaceuticals. New means of drug discovery – such as the use of stem cells – have elicited debate about the relative values placed on the status of the embryo and the potential treatment for intractable conditions that could result from stem cell research. Finally, the overall emphasis on drugs as the first line defense against what ails us has provoked some societal soul-searching. In this chapter, we review some of the ethical issues attendant to drug production and distribution, including issues of safety, justice, economic inequality, and the changing demands for drugs that exceed therapeutic uses. Suggestions are made to make pharmaceutical companies more responsive to these issues and to make oversight bodies more responsible for their roles.
has issue date	2007-12-31(xsd:dateTime)
bibo:doi	10.1016/b0-08-045044-x/00025-0
has license	els-covid
sha1sum (hex)	c93491cabf0aa17c8ba1f05e01701e6bfe7a4fd1
schema:url	https://doi.org/10.1016/b0-08-045044-x/00025-0
resource representing a document's title	1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment
has PubMed Central identifier	PMC7152255
schema:publication	Comprehensive Medicinal Chemistry II
resource representing a document's body	covid:c93491cabf0aa17c8ba1f05e01701e6bfe7a4fd1#body_text
is schema:about of	named entity 'BIOETHICAL ISSUES' named entity 'MEDICINAL CHEMISTRY' named entity 'DRUG TREATMENT' named entity 'Drug Treatment' named entity 'death row' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software